File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Serum Hepatitis B Surface Antigen Levels During Five Years Entecavir Therapy In Asian Chronic Hepatitis B Patients

TitleSerum Hepatitis B Surface Antigen Levels During Five Years Entecavir Therapy In Asian Chronic Hepatitis B Patients
Authors
Issue Date2013
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 24-28 April 2013. In Journal of Hepatology, 2013, v. 58 n. Suppl. 1, p. S314, abstract no. 772 How to Cite?
AbstractBackground: Change in hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy in chronic hepatitis B (CHB) has not been well investigated. Aim: To determine the serologic, biochemical, virologic responses and resistance profile of continuous entecavir up to 5 years. Methods: 222 (70.7% male, median age 45 years) CHB patients started on entecavir between July 2005 and November 2007 were recruited. The rates of HBV DNA detectability, hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, and entecavir signature mutations up to year 5 were determined. Serum HBV DNA and HBsAg levels were measured by Cobas Taqman and Elecsys II assay respectively. Resistance profile was determined by a line probe assay (LiPA) for patients with detectable HBV DNA. Results: 222, 188, 173, 170 and 156 patients were followed up for 1, 2, 3, 4 and 5 years respectively. The rates of HBV DNA undetectability, HBeAg seroconversion for HBeAg-positive patients and ALT normalization (for patients with elevated baseline ALT) at year 5 were 97.4%, 55.7% and 91.4% respectively. 1 patient developed HBsAg seroclearance at year 2. 2 patients developed entecavir signature mutations at years 3 and 5 (rt180M, rt204V, rt184S/C/G/A and rt180M, rt204V, rt184I/L/F/M, rt202G, rt250V respectively), resulting in a cumulative resistance of 1.2% up to year 5. Among patients with 5 years of follow-up (n = 156), the median annual HBsAg decline was 0.116 (range −0.176 to 0.980) log IU/mL/year with HBeAg-positive patients having a greater median HBsAg decline when compared to HBeAg-negative patients (0.141 and 0.097 log IU/mL/year respectively, p = 0.021). Patients with significant HBsAg decline, defined as >0.25 log IU/mL/year (n = 31), when compared to patients without significant HBsAg decline, was associated with younger median age (43.5 and 49.3 years respectively, p = 0.014), HBeAg-positivity (54.8% and 34.7% respectively, p = 0.039), and higher median baseline HBV DNA levels (7.99 and 6.22 log IU/mL respectively, p<0.001). Conclusion: Entecavir for 5 years achieved excellent rates of virologic suppression and low rates of resistance. Serum HBsAg levels decreased gradually during treatment, with a higher rate of decline seen in younger HBeAg-positive patients. Acknowledgement: This study was supported by an unrestricted grant from Bristol-Myers Squibb.
DescriptionFulltext in: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf
Poster Session: 07c. Viral Hepatitis B & D: Clinical (Therapy, New Compounds, Resistance)
Persistent Identifierhttp://hdl.handle.net/10722/185004
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKWen_US
dc.contributor.authorLam, YFen_US
dc.contributor.authorFung, JYYen_US
dc.contributor.authorWong, DKHen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2013-07-15T10:23:47Z-
dc.date.available2013-07-15T10:23:47Z-
dc.date.issued2013en_US
dc.identifier.citationThe 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 24-28 April 2013. In Journal of Hepatology, 2013, v. 58 n. Suppl. 1, p. S314, abstract no. 772en_US
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/185004-
dc.descriptionFulltext in: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf-
dc.descriptionPoster Session: 07c. Viral Hepatitis B & D: Clinical (Therapy, New Compounds, Resistance)-
dc.description.abstractBackground: Change in hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy in chronic hepatitis B (CHB) has not been well investigated. Aim: To determine the serologic, biochemical, virologic responses and resistance profile of continuous entecavir up to 5 years. Methods: 222 (70.7% male, median age 45 years) CHB patients started on entecavir between July 2005 and November 2007 were recruited. The rates of HBV DNA detectability, hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, and entecavir signature mutations up to year 5 were determined. Serum HBV DNA and HBsAg levels were measured by Cobas Taqman and Elecsys II assay respectively. Resistance profile was determined by a line probe assay (LiPA) for patients with detectable HBV DNA. Results: 222, 188, 173, 170 and 156 patients were followed up for 1, 2, 3, 4 and 5 years respectively. The rates of HBV DNA undetectability, HBeAg seroconversion for HBeAg-positive patients and ALT normalization (for patients with elevated baseline ALT) at year 5 were 97.4%, 55.7% and 91.4% respectively. 1 patient developed HBsAg seroclearance at year 2. 2 patients developed entecavir signature mutations at years 3 and 5 (rt180M, rt204V, rt184S/C/G/A and rt180M, rt204V, rt184I/L/F/M, rt202G, rt250V respectively), resulting in a cumulative resistance of 1.2% up to year 5. Among patients with 5 years of follow-up (n = 156), the median annual HBsAg decline was 0.116 (range −0.176 to 0.980) log IU/mL/year with HBeAg-positive patients having a greater median HBsAg decline when compared to HBeAg-negative patients (0.141 and 0.097 log IU/mL/year respectively, p = 0.021). Patients with significant HBsAg decline, defined as >0.25 log IU/mL/year (n = 31), when compared to patients without significant HBsAg decline, was associated with younger median age (43.5 and 49.3 years respectively, p = 0.014), HBeAg-positivity (54.8% and 34.7% respectively, p = 0.039), and higher median baseline HBV DNA levels (7.99 and 6.22 log IU/mL respectively, p<0.001). Conclusion: Entecavir for 5 years achieved excellent rates of virologic suppression and low rates of resistance. Serum HBsAg levels decreased gradually during treatment, with a higher rate of decline seen in younger HBeAg-positive patients. Acknowledgement: This study was supported by an unrestricted grant from Bristol-Myers Squibb.-
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_US
dc.titleSerum Hepatitis B Surface Antigen Levels During Five Years Entecavir Therapy In Asian Chronic Hepatitis B Patientsen_US
dc.typeConference_Paperen_US
dc.identifier.emailSeto, WKW: wkseto2@hku.hken_US
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hken_US
dc.identifier.emailWong, DKH: danywong@hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WKW=rp01659en_US
dc.identifier.authorityFung, JYY=rp00518en_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.doi10.1016/S0168-8278(13)60774-6-
dc.identifier.hkuros215587en_US
dc.identifier.volume58en_US
dc.identifier.issueSuppl. 1-
dc.identifier.spageS314, abstract no. 772en_US
dc.identifier.epageS314, abstract no. 772en_US
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats